ASTCT Talks

ASTCT
  • ٠٫٠ (٠)
  • طب
  • يتم التحديث كل شهرين

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!

  1. ٣١ مارس

    Treatment Options for cGVHD: Adult vs. Pediatric Perspectives

    In this episode of ASTCT Talks, host Corey Cutler, MD of Dana-Farber Cancer Institute and Harvard University sits down with Nosha Farhadfar, MD, medical director of research for Sarah Cannon Research Institute’s transplant and cellular therapy program at Methodist Healthcare, and Pooja Khandelwal, MD, an associate professor within the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center, to discuss adult and pediatric treatment perspectives for cGVHD. Tune in for a conversation that covers: Adult and pediatric cGVHD treatment approaches,including frontline choices and the selection and effectiveness of medications.Expert practice experiences for use in cGVHD treatment.New therapeutics the experts are looking forward to in cGVHD treatment. This episode was made possible thanks to a grant from Incyte.

    ٢٩ د

  2. ١٣ يناير

    Best Practice Considerations for Infection Prevention and Management Post-CAR T

    In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children’s ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients. The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations. Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.Addressing Evidence Gaps: Insider insights into the expert panel’s deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence. Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.

    ٣٦ د

  3. ٦ يناير

    LIVE From ASH: Multiple Myeloma Treatment Redefined by Bispecific Antibodies and T-Cell Therapies

    In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting. The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

    ٢٨ د

  4. ١٦‏/١٢‏/٢٠٢٥

    What Clinicians Need to Know About Chronic GVHD and Immunity

    In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk. The discussion highlights: • How chronic GVHD independently contributes to immune deficits and infection susceptibility. • Infectious risks associated with FDA-approved therapies for chronic GVHD. • Common infections in this population and why vigilance matters. • Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety. This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD. Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.

    ٢١ د

  5. ١٦‏/١٢‏/٢٠٢٥

    Pulmonary Manifestations of Chronic GVHD

    In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians. For a deeper dive, explore Dr. Cheng’s many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.

    ٢٤ د

  6. ٠٢‏/١٢‏/٢٠٢٥

    Tackling Cognitive Challenges in Survivorship Care

    In this episode of ASTCT Talks, host Christina Ferraro, nurse practitioner from the Cleveland Clinic, sits down with Vanessa Kennedy, MD, from Stanford University, to address a critical aspect of survivorship: cognitive health, including issues like brain fog, memory lapses and reduced executive function. The discussion highlights: New ASTCT consensus guidelines on cognitive assessment.Practical strategies for operationalizing cognitive screening in busy clinical settings. How factors like anxiety, depression, sleep and polypharmacy influence cognition — and why addressing these is critical. Emerging interventions, from cognitive rehabilitation to surprisingly effective options like jigsaw puzzles.This episode offers actionable insights into supporting cognitive function and quality of life in survivorship care.

    ٢٤ د

  7. ٢٤‏/١٠‏/٢٠٢٥

    Titans of Transplant: Innovations in CAR T Cell Therapy

    In this episode of ASTCT’s Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy. From the groundbreaking ZUMA-1 trial to today’s expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.

    ٤١ د

  8. ١٦‏/١٠‏/٢٠٢٥

    Pharmacist Takeover: BCMA Bispecifics and CAR T-Cell Therapy

    In this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG. Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies, with a focus on ciltacabtagene autoleucel and idecabtagene vicleucel.

    ٣٨ د
مشاهدة الكل (٧١)

حول

ASTCT Talks is the official podcast of the American Society for Transplantation and Cellular Therapy (ASTCT). We chat with industry leaders from all areas of the blood and marrow transplantation and cellular therapy field, including doctors, physician assistants, pharmacists, nurses, administrators, social workers, and more. We hope you enjoy listening!

المعلومات

  • صناع العمل
    ASTCT
  • سنوات النشاط
    ٢٠٢٠ - ٢٠٢٦
  • الحلقات
    ٧١
  • التقييم
    ملائم
  • حقوق النشر
    © ASTCT
  • موقع البرنامج على الويب
    ASTCT Talks

قد يعجبك أيضًا